West Nile virus neuroinvasive disease associated with rituximab therapy
Authors:
- 29 May 2020
- journal article
- case report
- Published by Springer Nature in Journal of NeuroVirology
- Vol. 26 (4) , 611-614
Abstract
West Nile virus neuroinvasive disease (WNVND) manifests with meningitis, encephalitis, and/or acute flaccid paralysis. It represents less than 1% of the clinical syndromes associated with West Nile virus (WNV) infection in immunocompetent patients. Immunosuppressive therapy is associated with increased risk of WNVND and worse prognosis. We present a patient with WNVND during therapy with rituximab, and a review of the literature for previous similar cases with the goal to describe the clinical spectrum of WNVND in patients treated specifically with rituximab. Our review indicates that the most common initial complaints are fever and altered mental status, brain magnetic resonance imaging often shows bilateral thalamic hyperintensities, and cerebrospinal analysis consistently reveals mild lymphocytic pleocytosis with elevated protein, positive WNV polymerase chain reaction, and negative WNV antibodies. Treatment is usually supportive care, with intravenous immunoglobulins (IVIG) plus corticosteroids and WNV-specific IVIG also used. The disease is usually fatal despite intervention. Our patient’s presentation was very similar to prior reports, however demonstrated spontaneous improvement with supportive management only. WNVND is a rare and serious infection with poor prognosis when associated with rituximab therapy. Diagnosis is complicated by absent or delayed development of antibodies. The presence of bilateral thalamic involvement is a diagnostic clue for WNVND. There is insufficient evidence to recommend the use of corticosteroids or IVIG.Keywords
This publication has 11 references indexed in Scilit:
- Seronegative West Nile Virus Infection in a Patient Treated with Rituximab for Rheumatoid ArthritisThe American Journal of Medicine, 2017
- West Nile Virus Central Nervous System Infection in Patients Treated With Rituximab: Implications for Diagnosis and Prognosis, With a Review of LiteratureOpen Forum Infectious Diseases, 2015
- Donor-Derived West Nile Virus Infection in Solid Organ Transplant RecipientsTransplantation, 2014
- Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case reportBMC Research Notes, 2014
- West Nile Virus: Review of the LiteratureJAMA, 2013
- Impact of rituximab‐associated B‐cell defects on West Nile virus meningoencephalitis in solid organ transplant recipientsClinical Transplantation, 2010
- Fatal West Nile Virus Infection After Rituximab/Fludarabine–Induced Remission for Non-Hodgkin's LymphomaClinical Lymphoma Myeloma and Leukemia, 2005
- Transient parkinsonism in west nile virus encephalitisThe American Journal of Medicine, 2003
- Detection of IgG and IgM to West Nile VirusAmerican Journal of Clinical Pathology, 2003
- First Isolation of West Nile virus from a Patient with Encephalitis in the United StatesEmerging Infectious Diseases, 2002